Evidence map›Paper›PMID 35284529›Full record

ArticleHepatobiliary surgery and nutrition2022

Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: a randomized comparative study.

Peng-Peng Li, Gang Huang, Ning-Yang Jia, Ze-Ya Pan, Hui Liu, Yun Yang, Cheng-Jian He, Wan Yee Lau, Ye-Fa Yang, Wei-Ping Zhou

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatobiliary surgery and nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Peng-Peng Li *Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Gang Huang *Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Ning-Yang JiaEastern Hepatobiliary Surgery Hospital, Shanghai, China.
Ze-Ya PanEastern Hepatobiliary Surgery Hospital, Shanghai, China.
Hui LiuEastern Hepatobiliary Surgery Hospital, Shanghai, China.
Yun YangEastern Hepatobiliary Surgery Hospital, Shanghai, China.
Cheng-Jian HeEastern Hepatobiliary Surgery Hospital, Shanghai, China.
Wan Yee LauFaculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
Ye-Fa YangEastern Hepatobiliary Surgery Hospital, Shanghai, China.
Wei-Ping ZhouEastern Hepatobiliary Surgery Hospital, Shanghai, China.
Second Military Medical University · CNEastern Hepatobiliary Surgery Hospital · CNChinese University of Hong Kong · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Both portal vein embolization (PVE) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) have merits and demerits when used in patients with unresectable liver cancers due to insufficient volumes in future liver remnant (FLR). Methods: This study was a single-center, prospective randomized comparative study. Patients with the diagnosis of hepatitis B related hepatocellular carcinoma (HCC) were randomly assigned in a 1:1 ratio to the 2 groups. The primary endpoints were tumor resection and three-year overall survival (OS) rates. Results: Between November 2014 to June 2016, 76 patients with unresectable HBV-related HCC due to inadequate volume of FLR were randomly assigned to ALPPS groups (n=38) and TACE + PVE groups (n=38). Thirty-seven patients (97.4%) in the ALPPS group compared with 25 patients (65.8%) in the TACE + PVE group were able to undergo staged hepatectomy (risk ratio 1.48, 95% CI: 1.17-1.87, P<0.001). The three-year OS rate of the ALPPS group (65.8%) (95% CI: 50.7-80.9) was significantly better than the TACE + PVE group (42.1%) (95% CI: 26.4-57.8) (HR 0.50, 95% CI: 0.26-0.98, two-sided P=0.036). However, no significant difference in the OS rates between patients who underwent tumor resection in the 2 groups of patients was found (HR 0.80, 95% CI: 0.35-1.83, two-sided P=0.595). Major postoperative complications rates after the stage-2 hepatectomy were 54.1% in the ALPPS group and 20.0% in the TACE + PVE group (risk ratio 2.70, 95% CI: 1.17-6.25, P=0.007). Conclusions: ALPPS resulted in significantly better intermediate-term OS outcomes, at the expenses of a significantly higher perioperative morbidity rate compared with TACE + PVE in patients who had initially unresectable HBV-related HCC.

Indexed as

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)hepatocellular carcinoma (HCC)portal vein embolization (PVE)prognosisresection rate

Identifiers

PMID35284529
PMCPMC8847855
OpenAlexW3041456355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.